SIRT1 and lung carcinoma: Clinical data from lung cancer patients indicated that higher expression of SIRT1 and OXPHOS-associated proteins correlated with tumor recurrence and poor survival, supporting that OXPHOS inhibitors could be a part of a combination therapy for better clinical outcome in these patients [100].